GNMSF News and Press, Genmab A/S Dkk From 05/12/22

The following slide deck was published by Genmab A/S in conjunction with their 2022 Q1 earnings call. For further details see: Genmab A/S 2022 Q1 - Results - Earnings Call Presentation

Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Peter Virgil - Citigroup James Gordon - JPMorgan Wimal Kapadia - Bern...

The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market. Huge price loss in the past 12 months, but positive price gain in the past three years, is an apparently visible trend in Genomics-...

Genmab (GMAB) said an arbitral tribunal has ruled in favor of Johnson & Johnson's (NYSE:JNJ) Janssen Biotech in both matters related to royalty payments under their license agreement related to cancer drug daratumumab. On the first issue, the tribunal determined by maj...

Analysts continue to disbelieve that the Pfizer/BioNTech Comirnaty vaccine can have a future, while reality shows boosters are needed. Pfizer’s earnings from Comirnaty continue to distort the price of Pfizer stock; this will continue. The more difficult issue is to understa...

Seagen had achieved net product sales of $1.4 billion in 2021, which was an annual growth rate of 38%. TIVDAK was approved in September of 2021 for recurrent or metastatic cervical cancer, potential to expand use of the drug for squamous cell carcinoma of the head and neck. PADCEV...

The following slide deck was published by Genmab A/S in conjunction with their 2021 Q4 earnings call. For further details see: Genmab A/S 2021 Q4 - Results - Earnings Call Presentation

Genmab A/S (GMAB) Q4 2021 Earnings Conference Call February 16, 2022, 12:00 PM ET Company Participants Jan van de Winkel – President and Chief Executive Officer Anthony Pagano – Chief Financial Officer Anthony Mancini – Chief Operation Officer Tahi Ahmadi – Chief M...

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...